Exclusive-Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts

Novo Nordisk has eliminated its U.S. 'cardiometabolic educator' sales team, comprising several hundred staff focused on obesity and diabetes education, signaling an aggressive cost-cutting measure. This move is an early, previously unreported step in the broader restructuring and 9,000 global job cuts announced by new CEO Maziar Mike Doustdar, aimed at regaining market share and improving profitability after the company lost over $400 billion in market capitalization and dominance in the U.S. weight-loss drug market to rival Eli Lilly.

Analysis

Novo Nordisk (NVO) is executing a significant operational restructuring by eliminating its entire U.S. 'cardiometabolic educator' team, a commercial division of several hundred staff focused on obesity and diabetes education. This specific, previously unreported layoff is the first tangible evidence of a broader strategic shift under new CEO Maziar Mike Doustdar, which includes a planned 9,000 global job cuts. The move is a direct response to intense competitive pressure from Eli Lilly (LLY), which has eroded NVO's dominance in the U.S. weight-loss drug market and contributed to a market capitalization loss exceeding $400 billion since mid-last year. By dismantling a team for which its primary rival has no equivalent, NVO is signaling a decisive pivot towards a leaner cost structure and a more aggressive commercial model to regain ground and improve profitability. While the broader restructuring was initially viewed favorably by investors, this action underscores the severity of the market share battle with LLY and the urgency of NVO's turnaround efforts.

Key Decisions for Investors

• Investors in Novo Nordisk should view this aggressive cost-cutting as a necessary defensive maneuver; monitor for evidence that these operational changes can successfully stabilize market share and improve margins against its chief rival.
• For Eli Lilly investors, Novo Nordisk's move to emulate LLY's leaner commercial structure reinforces LLY's current competitive advantage and operational efficiency in the highly lucrative weight-loss drug market.
• This restructuring signals an intensification of competition and a potential shift away from broad educational marketing toward more direct commercial tactics, warranting a closer watch on sales and marketing expenses and their effectiveness for both companies.